Study design
MAY
This phase 3, observer-blind, placebo-controlled randomized study was conducted at 11 sites across the US between February 2018 and May 2019. Participants were randomized 1:1:1 at enrollment using sequence of random numbers centrally-generated in blocks of 6 participants. The vaccine scheme for each of the groups is shown in 